The drugs giant is asking its shareholders to approve a performance-based pay policy that could hand Pascal Soriot rewards of up to £18.7 million this year.
AstraZeneca chief s huge payday provokes investor revolt dailymail.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymail.co.uk Daily Mail and Mail on Sunday newspapers.
The newest weight loss drug on the market is facing a shortage of supply, according to the U.S. Food and Drug Administration. The FDA approved Zepbound in November as a weight loss management treatment for people with obesity, or those who are overweight with at least one related underlying condition, such as high blood pressure. As a diabetes drug, Zepbound is sold under the brand name Mounjaro, as the two medications contain the same active ingredient, tirzepatide.